- PRICING
- LIVE QUOTES
- LEARN
- HELP
EN
2 Profitable Stocks to Research Further and 1 We Avoid
Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential.
A business making money today isn’t necessarily a winner, which is why we analyze companies across multiple dimensions at StockStory. Keeping that in mind, here are two profitable companies that balance growth and profitability and one that may face some trouble.
One Stock to Sell:
Everforth (EFOR)
Trailing 12-Month GAAP Operating Margin: 4.9%
Evolving from its roots in IT staffing to become a high-end technology consulting powerhouse, Everforth (EFOR) provides specialized IT consulting services and staffing solutions to Fortune 1000 companies and U.S. federal government agencies.
Why Do We Avoid EFOR?
- Products and services are facing significant end-market challenges during this cycle as sales have declined by 3.7% annually over the last two years
- Sales are projected to be flat over the next 12 months and imply weak demand
- Falling earnings per share over the last five years has some investors worried as stock prices ultimately follow EPS over the long term
Everforth’s stock price of $32.91 implies a valuation ratio of 8.4x forward P/E. Dive into our free research report to see why there are better opportunities than EFOR.
Two Stocks to Watch:
Booking (BKNG)
Trailing 12-Month GAAP Operating Margin: 32.9%
Formerly known as The Priceline Group, Booking Holdings (NASDAQ:BKNG) is the world’s largest online travel agency.
Why Are We Positive on BKNG?
- Prominent and differentiated platform culminates in a best-in-class gross margin of 87%
- Healthy EBITDA margin of 36.4% shows it’s a well-run company with efficient processes, and its rise over the last few years was fueled by some leverage on its fixed costs
- Strong free cash flow margin of 35.3% enables it to reinvest or return capital consistently
Booking is trading at $164.00 per share, or 11.3x forward EV/EBITDA. Is now a good time to buy? Find out in our full research report, it’s free.
Boston Scientific (BSX)
Trailing 12-Month GAAP Operating Margin: 19.8%
Founded in 1979 with a mission to advance less-invasive medicine, Boston Scientific (NYSE:BSX) develops and manufactures medical devices used in minimally invasive procedures across cardiovascular, urological, neurological, and gastrointestinal specialties.
Why Do We Like BSX?
- Average organic revenue growth of 15.8% over the past two years demonstrates its ability to expand independently without relying on acquisitions
- Incremental sales over the last five years have been highly profitable as its earnings per share increased by 18.6% annually, topping its revenue gains
- Free cash flow margin grew by 12.3 percentage points over the last five years, giving the company more chips to play with
At $43.69 per share, Boston Scientific trades at 13.5x forward P/E. Is now the right time to buy? See for yourself in our comprehensive research report, it’s free.
High-Quality Stocks for All Market Conditions
ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI is taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.
Our AI system flagged Palantir before it ran 1,662% between October 2022 and February 2026. AppLovin before it ran 753% between February 2024 and February 2026. Nvidia before it ran 1,178% between January 2023 and February 2026. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+214% between June 2020 and June 2025). Find your next big winner with StockStory today.